|
Video: What is a Stock Split?
|
|
Outlook Therapeutics is a biopharmaceutical company. Co. is developing ONS-5010 (LYTENAVA (bevacizumab-vikg)) for use in the treatment of retina diseases such as wet age-related macular degeneration, diabetic macular edema and branch retinal vein occlusion. According to our OTLK split history records, Outlook Therapeutics has had 3 splits. | |
|
Outlook Therapeutics (OTLK) has 3 splits in our OTLK split history database. The first split for OTLK took place on November 13, 2006. This was a 1 for 200 reverse split, meaning for each 200 shares of OTLK owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 5 share position following the split. OTLK's second split took place on March 18, 2019. This was a 1 for 8 reverse split, meaning for each 8 shares of OTLK owned pre-split, the shareholder now owned 1 share. For example, a 5 share position pre-split, became a 0.625 share position following the split. OTLK's third split took place on March 14, 2024. This was a 1 for 20 reverse split, meaning for each 20 shares of OTLK owned pre-split, the shareholder now owned 1 share. For example, a 0.625 share position pre-split, became a 0.03125 share position following the split.
When a company such as Outlook Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the OTLK split history from start to finish, an original position size of 1000 shares would have turned into 0.03125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Outlook Therapeutics shares, starting with a $10,000 purchase of OTLK, presented on a split-history-adjusted basis factoring in the complete OTLK split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/15/2016 |
|
End date: |
04/22/2024 |
|
Start price/share: |
$671.60 |
|
End price/share: |
$8.09 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.80% |
|
Average Annual Total Return: |
-43.02% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$120.39 |
|
Years: |
7.86 |
|
|
|
Date |
Ratio |
11/13/2006 | 1 for 200 | 03/18/2019 | 1 for 8 | 03/14/2024 | 1 for 20 |
|
|